Drug General Information
Drug ID	D0S9BH
Former ID	DCL000588
Drug Name	Ozarelix
Indication	Prostate disease [ICD10:N42.9]		Phase 2	[531030]
Company	Spectrum
Structure		Download 2D MOL
Target and Pathway
Target(s)	Gonadotropin-releasing hormone receptor	Target Info	Modulator	[531030]
KEGG Pathway	Neuroactive ligand-receptor interaction
	GnRH signaling pathway
NetPath Pathway	IL1 Signaling Pathway
	IL2 Signaling Pathway
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Reactome	Hormone ligand-binding receptors
	G alpha (q) signalling events
WikiPathways	Gastrin-CREB signalling pathway via PKC and MAPK
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 531030	Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9.
Ref 531030	Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.